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Abstract
Validamycin A (Val-A) is an effective antifungal agent widely used in Asian countries as crop protectant. Validoxylamine A,
the core structure and intermediate of Val-A, consists of two C7-cyclitol units connected by a rare C-N bond. In the Val-A
biosynthetic gene cluster in Streptomyces hygroscopicus 5008, the ORF valL was initially annotated as a validoxylamine A 79-
phosphate(V7P) synthase, whose encoded 497-aa protein shows high similarity with trehalose 6-phosphate(T6P) synthase.
Gene inactivation of valL abolished both validoxylamine A and validamycin A productivity, and complementation with a
cloned valL recovered 10% production of the wild-type in the mutant, indicating the involvement of ValL in validoxylamine
A biosynthesis. Also we determined the structures of ValL and ValL/trehalose complex. The structural data indicates that
ValL adopts the typical fold of GT-B protein family, featuring two Rossmann-fold domains and an active site at domain
junction. The residues in the active site are arranged in a manner homologous to that of Escherichia coli (E.coli) T6P synthase
OtsA. However, a significant discrepancy is found in the active-site loop region. Also noticeable structural variance is found
around the active site entrance in the apo ValL structure while the region takes an ordered configuration upon binding of
product analog trehalose. Furthermore, the modeling of V7P in the active site of ValL suggests that ValL might have a similar
SNi-like mechanism as OtsA.
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Introduction
Aminocyclitols are a diverse class of bioactive compounds
produced by the Streptomyces genus [1]. Based on the chemical
structures, aminocylitols can be divided into several groups, such
as aminoglycoside, C7N-aminocyclitols and five-membered ring
aminocyclitols [2]. The C7N-aminocyclitols, including acarbose,
pyralomicin, salbostatin, cetoniacytone A and Val-A, have gained
increasing attention due to their extensive applications in
agriculture and medicine. Val-A is an antifungal agent isolated
from S. hygroscopicus var. limoneus and S. hygroscopicus var. jinggangensis
5008. It is used in many Asian countries as a crop protectant
against Rhizoctonia solani, which is a pathogenic fungus responsible
for various diseases in plants [3]. The antifungal capability of Val-
A is attributed to its ability to inhibit trehalase, a trehalose-
hydrolyzing enzyme. The inhibition of trehalase disrupts the
carbon supply and energy production in the fungi, which leads to
growth retardation and death of the pathogen [4].
The structure of Val-A consists of an unsaturated valienol unit
connected to a saturated validamine unit through a 1-1 a bond,
and a glucose unit attached to the validamine moiety [5]. Feeding
experiments indicated the 7-carbon unit in the Val-A structure
originates from the cyclization of sedoheptulose 7-phosphate [1].
Validamycin biosynthetic gene clusters had been independently
cloned from two above-mentioned producers [6,7]. The heterol-
ogous expression of eight genes, valABCGKLMN with valL
annotated as V7P synthase gene, rendered the surrogate host
with validamycin productivity [7]. Through multiple steps, the 2-
epi-5-epi-valiolone is proposed to be converted to NDP-valienol and
validamine 7-phosphate [7,8,9,10,11]. Subsequently, the rare
nitrogen-bridged twin-cyclitol core structure in Val-A arises from
the condensation of NDP-valienol and validamine 7-phosphate
(Figure 1). This coupling reaction was proved to be catalyzed by
the pseudoglycosyltransferase ValL, also named as VldE in the
biosynthetic gene cluster from S. hygroscopicus var. limoneus [7,12]. As
a result, a rare nonglycosidic C-N bond is formed between valienol
and validamine units with the retention of anomeric configuration
in each cyclitol ring. Several other natural products in the
aminocyclitol group also contain the unusual C-N bond, such as
acarbose, adiposin-1, salbostatin, trestatin, amylostatins and
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32033pyralomicin [1,13,14]. In addition to ValL/VldE, AcbS/GacS,
from Actinoplanes sp. SE50/110 and Streptomyces glaucescens respec-
tively, are also thought to be responsible for the C-N bond
formation in acarbose biosynthesis [15].
Due to the sequence similarity between ValL and E.coli T6P
synthase OtsA, ValL was regarded as T6P synthase with relaxed
specificity (Figure 2). However, recent biochemical experiments
have shown that ValL/VldE has no T6P synthase activity. It has
strict substrate specificity for GDP-valienol and validamine 7-
phosphate. The replacement of either cyclitol derivative with a
glucose analog abolishes the reaction [12].
Although the catalytic activity of ValL/VldE has been studied,
genetic evidence for its involvement in Val-A biosynthesis is not
available, and the structural aspect of the protein activity remains
unexplored. In this report, we present in vivo gene inactivation and
complementation of valL, and the crystal structures of apo ValL
and ValL/trehalose complex. The inactivation and complemen-
tation of valL indicates valL is an essential part of the Val-A
biosynthesis pathway. The 1.7 A ˚ crystal structure shows that the
binding site for V7P is well conserved in ValL and OtsA while the
binding site for the nucleotide substrate is different. The modeling
of V7P in the active site of ValL suggests that ValL might have a
similar SNi-like mechanism as OtsA.
Results and Discussion
Inactivation of valL abolishes validamycin A production
In order to genetically prove the involvement of valL in Val-A
biosynthesis, a 1.18-kb internal region of valL was replaced by an
aac(3)IV cassette in strain 5008. This was achieved by using a
pHZ1358-derived plasmid pJTU685, in which valL had been
replaced by aac(3)IV between a 2.98-kb left flanking and a 2.12-
kb right flanking sequences of valL (Figure 3a). The plasmid
pJTU685 was introduced into strain 5008 through conjugation,
and thiostrepton-sensitive and apramycin-resistant exconjugants
were selected. The mutants 5008DvalL were further confirmed
by PCR amplification. The valL mutant gave an expected 1.60-
kb PCR product, whereas the wild-type strain 5008 gave a 1.30-
kb product (Figure 3b). Fermentation broths of the mutants were
analyzed by HPLC and bioassay. No peak corresponding to Val-
A and validoxylamine A was detected by HPLC analysis
(Figure 3c), and inhibition of the fungus Pellicularia sasakii could
not be observed in the bioassay (Figure 3d), indicating a
complete loss of production of both compounds in the valL
mutants.
When a pPM927-derived integrative plasmid pJTU640, with an
intact valL under the control of PermE* promoter, was introduced
Figure 1. Reactions catalyzed by OtsA, ValL and chemical structures of related natural products. (a) The reaction catalyzed by OtsA. (b)
The reaction catalyzed by ValL. (c) Chemical structures of validoxyamine A, trehalose and validamycin A.
doi:10.1371/journal.pone.0032033.g001
Structure and Function of ValL
PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e32033Figure 2. Structure-based sequence alignment of ValL and OtsA from several species. The primary sequence of ValL is aligned with the
OtsA sequences from E. coli, Mycobacterium tuberculosis, and Candida albicans. The sequences are annotated with corresponding secondary
structures in ValL. Arrows represent b-sheets and helices represent a-helices. The active-site loops are shaded and the conserved residues are colored
in red. The residues involved in binding of V7P to OtsA are marked by *.
doi:10.1371/journal.pone.0032033.g002
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exconjugant was found to regain the productivity of Val-A and
validoxylamine A by HPLC analysis (Figure 3c). Both inactivation
and complementation experiments clearly demonstrated that valL
is essential for the biosynthesis of Val-A and its intermediate
validoxylamine A.
Figure 3. Inactivation of valL and complementation of the mutant. (a) Schematic representation of the replacement of an 1.18-kb internal
fragment of valL with the 1.4-kb aac(3)IV. In shuttle plasmid pJTU685, aac(3)IV was inserted between the 2.98-kb and 2.12-kb genomic fragments
originally flanking the deleted 1.18-kb region. While wild-type S. hygroscopicus 5008 should give a 1.30-kb PCR-amplified product, mutant 5008DvalL
should yield a 1.60-kb product by using a pair of primers, valL-Det-F and valL-Det-F. (b) PCR analysis of wild-type S. hygroscopicus 5008 and valL
mutant. (c) HPLC profiles of the standards, 5008, 5008DvalL, and 5008DvalL::pJTU640. Plasmid pJTU640 is an integrative plasmid cloned with intact
valL under the control of PermE* promoter. (d) Bioassay comparison between the 5008 and 5008DvalL. One mL of fermentation supernatant was
mixed with 14 mL of melted 0.8% agar. An agar plug with the fungal indicator Pellicularia sasakii was transferred to the center of the agar plate. After
24 h incubation at 30uC, the diameter of the colony was measured, which is inversely related to the inhibitory potency.
doi:10.1371/journal.pone.0032033.g003
Figure 4. Three-dimensional structures of ValL and GT-B glycosyltransferases. A diagram showing N-terminal domain (green), C-terminal
domain (blue) and the cleft harboring the active site. (a) ValL. (b) OtsA. (c) T4 b-glucosyltransferase.
doi:10.1371/journal.pone.0032033.g004
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The overall structure of ValL closely resembles the classic fold of
‘‘GT-B’’ glycosyltransferases (Figure 4). It harbors two domains,
each of which contains a b/a/b Rossmann fold, and an active site
at their interface. The N-terminal domain of ValL (1–263) consists
of twelve b-strands flanked by nine helices. The C-terminal
domain (264–481), which adopts a similar fold, consists of six
parallel b-strands surrounded by eight helices. Also found in the
ValL structure is a kink between last two C-terminal helices, which
is the common feature of GT-B enzyme family. The kink directs
the last C-terminal helix into the vicinity of the N-terminal domain
and causes the residues in the helix to interact with the N-terminal
domain. ValL exists as a dimer in the crystal and the dimerization
interface, which lies at the opposite side of the active site, covers a
wide region on the surface (the buried area 10,834 A ˚ 2). The
dynamic scattering experiment indicated that ValL forms a dimer
in solution(data not shown). It is unclear why ValL forms a dimer.
In other organisms, such as Saccharomyces cerevisae, the T6P synthase
and phosphatase form a multiunit complex [16]. It is possible that
the dimerization of the enzyme could facilitate the formation of
the ValL/phosphatase complex which might be important for its
function.
Comparison between OtsA and ValL Structures
The overall structure of ValL is analogous to that of OtsA. The
secondary structure matching between these two structures
resulted in a root mean square deviation(RMSD) of 1.83 A ˚ over
369 residues. A notable difference lies in the loop region ranging
from Arg12 to Thr35 (Figure 2). As the shortest loop in the GT-B
protein family, the active site loop in OtsA structure is located
within the cleft between N-terminal and C-terminal domains. In
the ValL structure, due to a 9-residue insertion, the active-site
loop protrudes out of the cleft and forms part of a 12-strand b-
sheet at N-terminal domain. Furthermore, the b5a n db6 strands
of ValL are significantly larger than the counterparts in OtsA.
The a2 helix is unique for ValL as the corresponding sequence in
Figure 5. Superposition of OtsA and ValL structures. (a) Ribbon diagram overlap. The ribbon diagram of OtsA (colored in blue) is superposed
with that of ValL(colored in green). The boxed region shows the main difference between two structures. (b) Active site overlap. The active site
residues responsible for V7P binding in OtsA (colored in blue) are superposed with the active site residues in ValL(colored in green). Residue-labelsi n
ValL are shown.
doi:10.1371/journal.pone.0032033.g005
Figure 6. Close-up view of the active site with a trehalose molecule in it. (a) A ribbon diagram showing a trehalose molecule binds in the
active site located at the junction of N-terminal (cyan) and C-terminal (blue) domains. (b) Close-up view of the trehalose binding site. The electron
density map(in blue) is part of an omit map calculated with coefficients |Fobs| -|Fcalc| and phases from an omit model of ValL/trehalose complex
without the trehalose molecule. The map has 1.7 A ˚ resolution and is contoured at 3s level. (c) Hydrogen bond network formed between the
trehalose molecule and the residues around it.
doi:10.1371/journal.pone.0032033.g006
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thebindingofV7PinOtsAaremostlyconservedinValL(Figure5b).
In contrast, the residues within hydrogen bonding distance to the
uridine moiety are different, which is consistent with ValL’s
preference for GDP-valienol as its substrate. Although the
nucleosides in ValL and OtsA substrates are distinctive, the
replacement of UDP-glucose with GDP-glucose does not render
ValL with T6P synthase activity [12]. Therefore, nucleoside is not
the determinant for ValL and OtsA substrate specificity.
Binding of trehalose and modeling of validoxylamine A
79-phosphate in the active site
To probe the mechanism of reaction catalyzed by ValL, its
product analogs, trehalose and validoxylamine A, were used to form
complex with ValL. The co-crystallization of ValL/trehalose led to
the determination of ValL/trehalose complex structure. The
electron density at the junction of N-terminal and C-terminal
domains unambiguously indicates the location of trehalose
embedded in the active site (Figure 6a & 6b). The location of
trehalose allows clear description of interaction between the
trehalose molecule and ValL. The trehalose molecule associates
withtheactivesitethroughanetworkofhydrogenbonds(Figure6c).
The hydroxyl group on trehalose C69 interacts with guanidine side
chains of Arg12, Arg326; the hydroxyl groups on C39 and C49 form
hydrogen bonds with Asn325 amide side chain; the hydroxyl groups
on C2 form hydrogen bond with Asp383 side chain carboxylate.
Also the binding of trehalose molecule is maintained through the
interaction between the exocyclic hydroxyl groups and the protein
backbone. The hydroxyl group at C3 position forms hydrogen
bonds with the backbone amide groups on Gly384, Gln385,
Asn386; the hydroxyl group at C4 position forms hydrogen bonds
with backbone amide groups on Asn386 and Leu387.
Figure 7. Modeling of V7P in the ValL active site. The V7P
molecule is modeled in the active site of ValL using the docking
program AutoDock. The ValL/V7P complex model (colored in green) is
superposed with OtsA/V7P complex structure (colored in blue). The V7P
molecules are shown in cylinders and the proteins are shown in
ribbons.
doi:10.1371/journal.pone.0032033.g007
Figure 8. The proposed mechanism for ValL. Adopted from the mechanism of OtsA, a SNi-like mechanism is proposed for ValL. The transition
state is enclosed in brackets and GMP is designated as X.
doi:10.1371/journal.pone.0032033.g008
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complex proved to be fruitless, the V7P molecule was modeled
into the active site of ValL to illustrate the binding site of its
natural product. The modeling result indicates apo ValL active
site could accommodate V7P molecule readily. The superposition
of ValL/V7P complex and OtsA/V7P complex structures shows
that V7P adopts similar positions in both active sites (Figure 7). A
SNi-like mechanism was proposed for the reaction catalyzed by
ValL [12]. The oxocarbenium-like transition state involves the
carbonyl oxygen on the protein backbone and GDP-valienol.
Based on OtsA/V7P structure, a slightly different SNi-like
mechanism was proposed for V7P synthesis [17,18]. As illustrated
by the hydrogen bond formed between donor phosphate oxygen
O3B and bridging NH on V7P, a transition state is formed with
C1 carbon on cyclohexenyl moiety, NH2 group on validamine 7-
phosphate and O3B on donor phosphate [17]. As the active site
residues are highly conserved between OtsA and ValL, the
mechanism of ValL is likely to be homologous to that illustrated by
the OtsA/V7P complex structure(Figure 8).
Structural change induced by the binding of trehalose
The structure of apo ValL contains two molecules in the
asymmetric unit. The SSM alignment shows the backbone of chain
A and chain B matches well with an RMSD of 0.606 A ˚ across 461
Ca atoms. However, a significant discrepancy has been observed in
the region encompassing residue 88–110 (Figure 9). In chain A,
these residues form two adjacent helices. In contrast, in chain B, this
region consists of an N-terminal loop and a C-terminal a-helix.
Interestingly, in the ValL/trehalose complex structure, the folding
of residues88–110 is exactly thesameasthat inchainA ofapoValL
structure. This region forms part of the acceptor binding site. It is
possible that this part of the protein folds in different ways and once
the active site is occupied by the ligand, the ligand forces the
surrounding residues to form an ordered folding as in the ValL/
trehalose complex structure. The ligand-induced structural change
has been observed in other GT-B glycosyltransferases. In OtsA,
significant change can be observed in the active site loop and
adjacent region when the associated ligand was changed from
glucose-6-phosphate to UDP-glucose. The structural change
observed in OtsA and ValL is restricted in the acceptor domain
while the relative orientation of the donor and acceptor domains
stays the same [19]. In contrast, the binding of UDP in phage T4 b-
glucosyltransferase induces a 14-degree domain rotation which
results in a closed conformation [20]. It is noticeable that all the
OtsA structures available are protein/ligand complex structures
[17,19,21]. The apostructureof ValL thus demonstrates for the first
time the structural characteristics of this class of retaining enzymes
in the apo form, which sheds light on the conformational changes
accompanying substrate binding and enzyme activation.
Although V7P binding residues in OtsA are conserved in ValL,
Tyr 76 in OtsA is an exception. In the OtsA/V7P complex
structure, Tyr76 is responsible for binding of the acceptor
phosphate group and positioning the Arg9 to accommodate the
substrate [21]. Based on the sequence alignment, Gln96 in ValL
corresponds to Tyr76 in OtsA (Figure 2). Interestingly, Gln96 in
ValL adopts two positions in the apo form, one pointing towards
active site (Figure 10a) and one pointing away from active
site(Figure 10b). However, in the presence of trehalose, Gln96
takesanordered positiontowardthetrehalosemolecule(Figure10c).
As a result, it forms a water-bridged hydrogen bond with Arg326
which is responsible for the substrate binding. It is noteworthy that
Figure 9. Structural variance in the region encompassing 88–
110 residues of ValL. ValL/trehalose complex structure and ValL apo
structure are superposed with each other. The 88–110 regions in chain
B of ValL/trehalose complex structure(in blue) and chain B of ValL apo
structure (in green) are shown as ribbons. The rest of the molecules are
shown as worms.
doi:10.1371/journal.pone.0032033.g009
Figure 10. Change of orientation at Gln96 upon occupation of the active site. (a) In the structure of apo ValL, the region encompassing
residues 88–110 on chain A has a closed configuration. As a result, the residue Gln96 adopts an orientation pointing towards the active site which is
marked by Arg12 and Arg326. (b) On chain B of apo ValL, the region 88–110 takes an open configuration and the residue Gln96 points away from the
active site (c) In the structure of ValL/trehalose complex, the segment of residues 88–110 takes a single closed configuration with Gln96 pointing
towards the active site.
doi:10.1371/journal.pone.0032033.g010
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region(residues 88–110) takes alternative configuration upon
trehalose binding. It is possible that this region serves as a gate
which is responsible for opening and closing of the active site.
Materials and Methods
Bacterial strains, media, and cultivation
S. hygroscopicus var. jinggangensis 5008 and its derivatives were
grown either on solid SFM medium or in modified liquid TSBY
medium (with 10.3% sucrose). Fermentation was carried out at
37uC for 5 days. E. coli strains were cultivated at 37uC in Luria-
Bertani medium or on Luria-Bertani agar plates. E. coli DH10B
(GIBCO-BRL), ET12567 (pUZ8002) [22] and BW25113 (pIJ790)
[23] were used as E. coli hosts for plasmid construction, E. coli-
Streptomyces conjugation, and ReDirect technology, respectively
[23].
Construction and complementation of the valL-disrupted
mutant
The inactivation of gene valL was achieved by replacing with a
cassette of apramycin-resistant marker aac(3)IV using a PCR-based
ReDirect technology [23]. A 6.3-kb BclI fragment containing valL
was cloned to pHZ1358 [24] and generated pJTU685. The
cassette was amplified using plasmid pIJ773 as template and a pair
of primers valL-targeting-F (59-GCCAACCTGATGTGGG-
CGGCGAACAACTACGGCTGGGACattccggggatccgtcgacc-39)
and valL-targeting-R (59-TCAGAGGTCTGCTCGTGTCGAG-
ACTGCCGGTGCGGTGTCtgtaggctggagctgcttc-39), and pIJ773
homologous sequences were in lowercase. E. coli BW25113/
pIJ790 bearing pJTU685 was electroporated with the amplified
cassette. Mutated plasmid was firstly introduced into non-
methylating E. coli ET12567 pUZ8002) through transformation
and then transferred into S. hygroscopicus 5008 by intergeneric
conjugation [9]. Exconjugants with double cross-over were
selected for their apramycin resistance and named as LL2. The
allelic replacement of valL in the LL2 mutant was confirmed by
PCR amplification with the primers of valL-Det-F (59-
CCGGCGTCCTCAACATC-39) and valL-Det-R (59 -TGC-
TCGTGTCGAGACTGC-39).
For the complementation of the mutant, PCR-amplified valL
was cloned into pJTU968 [11] through EcoRI and NdeI
digestions to generate pJTU634. A 1.7-kb fragment with valL
was cleaved by EcoRI and MunI and cloned into pPM927
digested with EcoRI [25]. The new plasmid, pJTU640, was
introduced into LL2 through conjugation, and exconjugants were
selected with 25 mg/mL thiostrepton. The exconjugants were
named as LL2-1 and investigated through fermentation, HPLC
analysis, and bioassay as previously described [9].
Expression and purification of ValL
Gene valL was cloned into pET28a vector between EcoRI and
BamHI recognition sites. The pET28a-ValL plasmid was trans-
formed into E. coli BL21(DE3), and a single colony was used to
inoculate a 10 mL overnight culture containing 50 mg/mL
kanamycin. Then the culture was used to inoculate 3L LB broth,
and the culture was grown at 37uC until OD600 reached 0.5. The
protein expression was induced with 0.3 mM Isopropyl b-D-1-
thiogalactopyranoside (IPTG), and the incubation was continued
for another 12 hours at 18uC. Cells were collected by centrifugation
at 6,000 g, 4uC for 10 minutes. The resulting cell pellet was
resuspended in 30 mL buffer containing 20 mM Tris, 0.5 M NaCl,
pH 7.9. The cells were lysed with French Press, and the cellular
debris was removed by centrifugation at 40,000 g for 20 minutes.
The recombinant ValL was purified by chromatography with Ni-
NTA resin. The bound protein was washed with wash buffer
(30 mM imidazole, 20 mM Tris, 0.5 M NaCl, pH 7.9) and eluted
with elution buffer (200 mM Imidazole, 20 mM Tris, 0.5 M NaCl,
pH 7.9). The protein content in each fraction was resolved on
sodium dodecyl sulfate (SDS) gel before appropriate fractions were
pooled and further purified with size-exclusion chromatography on
a Superdex 75 column (16/60,G. E. Healthcare) equilibrated with
0.5 M NaCl, 20 mM Tris, PH 7.5. The protein was then
concentrated with AmiconH Ultra-4 Centrifugal Filter Units, and
the concentration was estimated spectrometerically at OD280.
Table 1. Data collection and refinement statistics.
Native ValL SeMet ValL
Data collection
Space group P21 P21
Cell dimensions
a, b, c (A ˚) 80.7, 46.7, 123.9 79.7, 45.8, 115.0
a, b, c(u) 90.0, 108.1, 90.0 90.0, 107.36, 90.0
Resolution (A ˚)
1 40.96–1.7(1.79–1.7) 45.8–1.7(1.79–1.7)
Wavelengths(A ˚) 0.9792 0.9792
Rmerge 0.083(0.552) 0.058(0.718)
I/s(I) 22.2(5.0) 17.2(2.1)
Completeness (%) 97.7(87.6) 99.1(94.2)
Redundancy 7.2(6.4) 7.1(5.9)
Wilson B-factors(A ˚2) 13.0 23.6
Anomalous completeness 98.5(92.5)
FOM/DM FOM
2 0.42/0.74
Refinement
Resolution (A ˚) 40.96–1.7(1.79–1.7) 45.8–1.7(1.79–1.7)
No. reflections 90507 82832
Rwork/Rfree
3 0.179/0.209 0.162/0.214
Number of atoms
Protein 7387 7181
Trehalose 46
Water 828 627
Average B-factor (A ˚2)
Protein 9.96 30.61
Trehalose 21.62
Water 21.64 40.21
R.m.s deviations
Bond lengths (A ˚) 0.009 0.011
Bond angles (u) 1.221 1.432
Ramachandran plot
4
Favored region (%) 98.19 97.12
Allowed region (%) 1.49 2.47
Outliers (%) 0.32 0.41
PDB code 3T5T 3T7D
1Data in the parenthesis was calculated based on the highest resolution shell.
2Mean figure of merit with or without density modification.
3R-factor=(Shkl||Fo|-|Fc||)/Shkl|Fo| where Fo and Fc are the observed and
calculated structure factors respectively. Rfree was calculated with a randomly-
selected 5% subset which was excluded from the refinement process.
4Statistics of Ramachandran plot were calculated with MolProbity.
doi:10.1371/journal.pone.0032033.t001
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literature and purified as native protein [26]. In brief, 5 ml of
overnight culture was used to inoculate 3L M9 medium
supplemented with 50 mg/mL kanamycin, 2 mM MgSO4,
0.1 mM CaCl2, and 5 g/L glucose. The culture was grown at
37uC until OD600 reached 0.6. Then lysine, phenylalanine, and
threonine were added at 100 mg/L, isoleucine, leucine, and valine
were added at 50 mg/L, and L-selenomethionine was added at
60 mg/L.Afterincubationfor15 min, 0.3 mMIPTG wasadded to
induce the protein expression and the incubation was continued for
another 12 hours at 18uC.
Crystallization and data collection
Crystals of native ValL were grown by the hanging-drop vapor-
diffusion method. Briefly, 1 mL of protein (10 mg/mL) was mixed
with the precipitant solution containing 30% (w/v) polyethylene
glycol 4000, 200 mM MgCl2, 100 mM Tris-HCl (pH8.5). The
mixture was allowed to equilibrate over a well filled with 150 mL
precipitant solution. The crystals appeared after overnight
incubation at 20uC and reached their maximum size three days
later. Selenomethionine-labeled ValL crystals were grown in the
same manner. To obtain ValL/trehalose complex structure,
5 mM trehalose was incubated with the enzyme for 30 min prior
to mixing with the precipitant solution. A cryo-protectant solution
was made by supplementing precipitant solution with 30%
trehalose. The crystals were immersed in the cryoprotectant
briefly before frozen in liquid nitrogen.
Diffraction data were collected at 100 k from selenomethionine-
labeled ValL crystals at the selenium absorption edge with a Mar
350 CCD detector on beam-line BL17U, Shanghai Synchrotron
Radiation Facility (SSRF), Shanghai, China. The data set was
indexed with XDS package and scaled with Scala [27,28]. Initial
phases were obtained by single-wavelength anomalous diffraction
(SAD) using the anomalous scattering caused by the selenomethi-
onine incorporated at the methionine sites. All 16 selenium sites in
the asymmetric unit were located with PHENIX package and the
phase was refined with a figure of merit of 0.42 to 2 A ˚ [29]. The
phase was further improved with DM program in the CCP4
package(figure of merit=0.74) [30]. The resulting electron density
map was of very good quality and side-chains of 80% residues
could be automatically built with PHENIX [29]. The manual
building was done with Coot and the structure was refined with
PHENIX after each building cycle [31]. Portion of the data (5%)
was set aside to calculate free R factor, which was used to monitor
the bias throughout the model building process [32]. The
stereochemistry of the model was validated at the late stage of
manual building with MolProbity [33]. Native data set was
collected at 100 k with a Mar 165 detector on beam-line 3W1A,
Beijing Synchrotron Radiation Laboratory (BSRF), Beijing,
China. The native structure was solved by molecular replacement
with Phaser, using semet ValL structure as the search model [34].
Data parameters and refinement statistics are summarized in
Table 1. The V7P molecule was modeled into apo ValL structure
using program AutoDock4.2 [35]. Autodock Tools was used to
preparing the protein and ligand. The grid box size was set at
70670670 A ˚. The center (20.920, 10.832, 57.006) of the box was
chosen according to the position of key residues in the pocket. All
of the docking decoys were clustered with a cut-off limit of 2 A ˚
according to RMSD.
Data deposition
The atomic coordinates and the structure factors of apo ValL
and ValL/trehalose complex have been deposited in the Protein
Data Bank (www.rcsb.org) with the accession codes of 3T5T and
3T7D respectively.
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